Dr. Larry Corey Named New Member of the Institutes of Medicine

Monday, October 13, 2008 General News
Email Print This Page Comment
Font : A-A+

SEATTLE, Oct. 13 Larry Corey, M.D., senior vice presidentand co-director of the Vaccine and Infectious Disease Institute at FredHutchinson Cancer Research Center, today was named as one of 65 new members ofthe prestigious Institutes of Medicine (IOM).

Election to the IOM is considered one of the highest honors in the fieldsof health and medicine and recognizes individuals who have demonstratedoutstanding professional achievement and commitment to service. Members areelected through a highly selective process that recognizes people who havemade major contributions to the advancement of the medical sciences, healthcare, and public health.

"I am honored by the recognition," Corey said. With a tip of the hat tothose who work in his labs, Corey added, "I thank all of the smart fellows,post docs, technicians and collaborators who have made me look so good overthe years. I hope I continue to stay out of their way and allow them to pursuetheir ideas, with just the right touch of guidance from me."

With their election to the IOM, members make a commitment to volunteer asignificant amount of time to IOM committees, which engage in a broad range ofstudies on health policy issues.

Corey is principal investigator of the HIV Vaccine Trials Network, whichis based at the Hutchinson Center. He is also head of the University ofWashington's Virology Division and is a professor of medicine and laboratorymedicine at the UW School of Medicine.

Research in Corey's labs includes studies dealing with the pathogenesis,prevention and treatment of HIV and herpes virus infections. Theseinvestigations include the development of experimental vaccines for bothgenital herpes and HIV. The labs have also pioneered novel tests fordiagnosing and monitoring therapies for viral infections.

Contact: Kristen Woodward, 206-667-5095 or kwoodwar@fhcrc.org

SOURCE Fred Hutchinson Cancer Research Center


Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store

Facebook